News

Nov 5, 2018

Slenyto® (PedPRM) was approved by EMA for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient

Jul 30, 2018

NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION FOR SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH AUTISM SPECTRUM DISORDER (ASD) (Read more)

May 7, 2018

Neurim Pharmaceuticals attends the INSAR Congress in Rotterdam, The Netherlands, May 9-11, 2018

Apr 16, 2018

Neurim sponsors a Satellite Symposium “Navigating through the Insomnia Roadmap in Children with ASD” at IPSA 2018, Paris, France.

Jan 17, 2018

Neurim Pharmaceuticals’ New Paediatric Prolonged-Release Melatonin (“PedPRM”) to Be Marketed by BIOCODEX Oy in Finland (Read more)

Dec 19, 2017

Circadin is celebrating 10 years in market!

Oct 15, 2017

Positive Phase III Results for Neurim Pharmaceuticals’ Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder (ASD) Presented at the World Sleep Congress in Prague (Read more)

Sep 25, 2017

Neurim Pharmaceuticals’ New Paediatric Prolonged-Release Melatonin (“PedPRM”) to Be Marketed by Flynn Pharma in UK and Ireland (Read more)

Sep 24, 2017

Positive Results of Pivotal Phase III Study of Pediatric Prolonged-Release Melatonin (PedPRM) for Insomnia in Children with Autism Spectrum Disorder (ASD) to be Presented at the World Sleep Congress in Prague on October 9th

Jul 3, 2017

Circadin® 2mg (prolonged-release melatonin) is now funded for insomnia in children and adolescents with Neurodevelopmental Disorders in New Zealand

Jun 25, 2017

Circadin® 2mg (prolonged-release melatonin) is now commercially available in Argentina

Mar 29, 2017

Neurim Pharmaceuticals Grants Exeltis Marketing Rights for Paediatric Prolonged-Release Melatonin (“PedPRM”) in Spain (Read more)

Mar 13, 2017

Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin (“PedPRM”) to be Marketed by Biocodex in France (Read more)

Dec 6, 2016

Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin (“PedPRM”) to be Marketed by Kuhnil Pharmaceutical in South Korea (Read more)

Nov 16, 2016

Neurim Pharmaceuticals Grants Aspen Australia Marketing Rights for Paediatric Prolonged-Release Melatonin (“PedPRM”) in Australia and New Zealand (Read more)

Nov 2, 2016

Neurim Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase III Trial of Paediatric Prolonged-Release Melatonin (“PedPRM”) for Sleep Disturbances in Children with Autism Spectrum Disorders (ASD) (Read more)

Oct 5, 2016

Circadin® 2mg (prolonged-release melatonin) is now commercially available in Honduras

Sep 28, 2016

Neurim Pharmaceuticals announces first patients’ enrollments in ReCOGNITION – phase II clinical trial of Piromelatine for mild Alzheimer’s disease (Read more)

Aug 2, 2016

Circadin® receives marketing authorization in Honduras

Jun 21, 2016

Circadin® is now reimbursed under a Temporary Recommendation for Use (RTU) in France for Children with Neurodevelopmental Disorders (Read more)